Webinars

  • Contains 3 Component(s) Includes a Live Web Event on 01/28/2027 at 3:00 PM (EST)

    The substitution of hydrogen with deuterium — a stable, non-radioactive isotope — represents a subtle and mechanistically powerful strategy in modern drug discovery. This webinar will introduce DMPK scientists and medicinal chemists to the kinetic isotope effect (KIE), exploring the physicochemical basis by which the stronger C–D bond can attenuate drug metabolism and influence a compound's pharmacokinetic profile. Drawing on both preclinical and clinical examples, attendees will gain an appreciation for how deuterium incorporation can be leveraged in drug design and as a mechanistic probe for identifying the site of metabolism. The presentation will also address the limitations of this approach — including metabolic switching and when to expect scenarios where no isotope effect is observed. Attendees will leave with a practical, foundational framework for evaluating when and how deuterium substitution can be a meaningful tool in their DMPK and medicinal chemistry toolkit.

  • Contains 3 Component(s) Includes a Live Web Event on 12/08/2026 at 12:00 PM (EST)

    Biotransformation science is critical to understanding the metabolic fate, pharmacokinetics, safety, and efficacy of new therapeutics. Biotransformation Stories highlights emerging research from doctoral trainees applying both established and evolving approaches to drug and xenobiotic metabolism. Emily Gracey will explore advanced human in vitro models for studying drug metabolism and toxicology, including 3D cultures, organoids, induced pluripotent stem cell-derived models, and microphysiological systems. These technologies offer opportunities to better recapitulate human physiology, improve preclinical translation, and complement conventional 2D cultures and animal models. Ian Levasseur’s presentation will examine the metabolism of BKI-1708, a promising anti-Cryptosporidium agent that forms an unusual, pharmacologically active hemiaminal metabolite. Using human liver microsomes, selective CYP inhibition, recombinant enzymes, and LC-MS/MS, CYP2C8 was identified as the primary enzyme responsible for metabolite formation, illustrating how mechanistic biotransformation studies can inform pharmacokinetics and drug–drug interaction risk. These stories will showcase how emerging scientists are addressing contemporary biotransformation challenges and provide a forum for engagement between academic trainees and industrial DMPK scientists.

Events

  • Contains 3 Product(s)

    This virtual workshop will focus on the impact of small organic molecule metabolism science on both drug discovery and drug development. This three day workshop will dissect the types of in vitro and in vivo drug metabolism studies conducted to support the drug discovery-development pipeline, including the experimental and analytical techniques used and the impact of the data generated. Some of the exciting topics to be covered are: the importance of drug metabolites, analytical techniques of metabolite ID, prediction of human circulating metabolite profiles, metabolite biosynthesis, human ADME study strategies and impact, and both the pharmaceutical industry and regulatory perspectives on the value of human ADME studies and drug metabolism science. Each session of this workshop will feature 4-5 expert speakers, a daily panel discussion, and poster sessions; the latter will be selected from the pool of abstracts from the students and industry attendees.